Every 10-Q that UMeWorld Ltd (UMEW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UMEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UMEW filings page.
UMeWorld Inc. develops functional nutrition and DAGola®-branded DAG cooking oils, now selling mainly through distributors in China. For the nine months ended June 30, 2026, revenue rose to $1,039,001 from very limited prior-year sales, producing modest gross profit of $62,511. Most revenue (about 99.57%) came from PRC customers, with U.S. sales remaining nominal. Inventory expanded to $890,686 as the company stocked product for Asia-Pacific distribution, while accounts receivable climbed to $531,065.
The business remains unprofitable: net loss for the nine-month period was $337,062, and cash was only $86,259 against current liabilities of $1,818,772, resulting in a working capital deficiency of about $306,312 and a stockholders’ deficit of $306,312. Management states that recurring losses, negative working capital, and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern. Operations are highly concentrated: two Chinese customers provided essentially all revenue and one Chinese supplier accounted for 99.83% of cost of revenues. Disclosure controls and procedures were deemed not effective due to limited accounting personnel and segregation-of-duties issues, though remediation efforts have begun.
UMeWorld Inc. reported a sharp ramp-up in sales but remains deeply unprofitable and financially strained. Revenue for the three months ended March 31, 2026 rose to $351,187 from $411 a year earlier, driven mainly by distributor sales in China. For the six-month period, revenue reached $498,642.
Despite this, gross profit was modest at $15,152 for the quarter and $19,694 year-to-date, while operating expenses climbed, producing a quarterly net loss of $105,450 and a six‑month net loss of $244,177. Cash was $145,445 and total assets $1.52 million, against liabilities of $1.74 million and a stockholders’ deficit of $214,260, with a disclosed working capital deficiency of similar magnitude.
Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to pursue growth in functional nutrition markets and additional financing. The business has heavy concentration risks, with about 99.17% of six‑month revenue from China and roughly 88.94% from a single distributor, and relies on a specialized DAG oil supplier. During the quarter, UMeWorld issued 814,588 shares to convert $203,647 of related‑party advances and sold 500,000 shares for $150,000 of cash. Disclosure controls and procedures were deemed not effective due to limited accounting personnel and segregation of duties, and remediation efforts are underway.
UMeWorld Inc. reported a sharp jump in quarterly revenue but remains deeply unprofitable and financially strained. For the three months ended December 31, 2025, revenue rose to $147,455 from $195 a year earlier, driven mainly by an initial distributor order in China.
The company still posted a net loss of $138,727 and ended the quarter with cash of $60,904, a working capital deficiency of about $462,599, and an accumulated deficit of $32,068,371, leading auditors to highlight substantial doubt about its ability to continue as a going concern.
Inventory ballooned to $1,682,509 from $13,410, while accounts payable increased to $1,670,243, reflecting heavy stocking and reliance on vendor credit. The business depends on a single Chinese supplier for specialized DAG oil and a key distributor that accounted for about 98% of quarterly revenue. Management is seeking additional capital and expanding distribution but also disclosed that disclosure controls and procedures were not effective due to internal control weaknesses.